baha the information company baha WebStation Terminal contact us Request free demo

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Free License - non-commercial use only

Region

Time Zone

UK
history
open
Sign Up / Login

For full-featured experience, please enable JavaScript.

HSBC Discount Zert MOR 30.12.2024/ DE000HG8YUD9 /

06/06/2024 11:00:07	Chg.0.000	Bid06/06/2024	Ask-	Underlying	Strike price	Expiration date	Option type
6.340EUR	0.00%	6.340 Bid Size: 10,000	- Ask Size: -	MORPHOSYS AG O.N.	- -	30/12/2024	Call

TeleTrader 11/04 Novartis launches offer for Morphosys at €68 per share

TeleTrader 12/03 Germany clears Novartis' MorphoSys $2.9B deal

TeleTrader 05/02 Novartis to acquire MorphoSys for $2.9B

GlobeNewswire 03/06/2021 CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...

GlobeNewswire 02/06/2021 Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

GlobeNewswire 27/04/2020 I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...

GlobeNewswire 28/10/2019 MOR106 clinical development in atopic dermatitis stopped for futility

GlobeNewswire 23/04/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...

GlobeNewswire 23/04/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...

GlobeNewswire 13/09/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

GlobeNewswire 13/09/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

GlobeNewswire 12/09/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...

GlobeNewswire 12/09/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...

GlobeNewswire 19/07/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

GlobeNewswire 19/07/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

GlobeNewswire 01/05/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...

GlobeNewswire 01/05/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...

GlobeNewswire 19/04/2018 Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market

GlobeNewswire 17/02/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...

GlobeNewswire 17/02/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...

GlobeNewswire 27/09/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...

GlobeNewswire 27/09/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...

GlobeNewswire 31/08/2017 Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/E...

GlobeNewswire 15/12/2016 Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MO...

GlobeNewswire 13/12/2016 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...